Lexaria Announces New R&D Plans for 2026
Rhea-AI Summary
Lexaria (Nasdaq:LEXX) announced its 2026 R&D Program launching a 5-week human study and two large animal studies to advance oral GLP-1 drug delivery and IP development.
The human study (GLP-1-H26-7) targets safety, tolerability and PK versus Wegovy tablets, with ~30 subjects per tablet arm and 15 in the capsule arm; recruitment may begin in April and a final report is expected in Q4 2026. Two animal studies (GLP-1-A26-1 and GLP-1-A26-2) with multiple arms (8–11 and 14–18 respectively) are planned to start in Q2 2026 with reports near end of Q3 2026. Work aims to generate new formulations, brain biodistribution data, and potential patentable IP to support pharma partnerships.
Positive
- Initiating a 5-week human study GLP-1-H26-7 focused on safety, tolerability and PK
- Human study sample sizes: ~30 subjects per tablet arm and 15 in capsule arm
- Two large animal studies planned (GLP-1-A26-1: 8–11 arms; GLP-1-A26-2: 14–18 arms)
- Timelines set: recruitment as early as April, animal studies starting Q2 2026, final reports Q3–Q4 2026
- Explicit objective to create new IP and attract pharmaceutical partnerships
Negative
- Larger human study sample size increases study costs
- Studies are contingent on ethics board approvals and third-party provider timelines
- Final designs may vary, introducing uncertainty to planned endpoints and timelines
Key Figures
Market Reality Check
Peers on Argus
LEXX fell 4.93% while peers were mixed: ASBP and PMN showed notable moves but in varying directions. Momentum scanner only flagged ASBP, down 4.76%, suggesting today’s action in LEXX is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Human pilot results | Positive | -8.7% | Final results from Human Pilot Study #5 on DehydraTECH-liraglutide vs Saxenda. |
| Jan 22 | Patent expansion | Positive | +2.1% | Six new patents granted, bringing total to 60 across major markets. |
| Jan 12 | CEO annual letter | Positive | +3.2% | Annual letter summarizing Phase 1b success, patents, MTA extension and financing. |
| Dec 30 | Phase 1b data update | Positive | -2.9% | Additional results from Phase 1b GLP-1-H24-4 showing safety and exploratory benefits. |
| Dec 23 | Primary endpoint met | Positive | -8.0% | Phase 1b GLP-1-H24-4 met primary safety/tolerability endpoint vs Rybelsus control. |
Recent history shows multiple positive GLP-1 and IP milestones, yet several such announcements coincided with negative next-day price moves, indicating a pattern of selling into good news.
Over the past few months, Lexaria has repeatedly highlighted progress with its DehydraTECH platform across GLP-1 drugs and CBD. Positive data from Phase 1b GLP-1-H24-4 and Human Pilot Study #5 emphasized safety and reduced adverse events versus injectable or oral controls. The company also expanded IP, growing to 60 patents, and detailed financing steps and R&D spend in filings and the CEO’s annual letter. Today’s 2026 R&D program plans build directly on this GLP-1 and brain-biodistribution work, aiming to advance human and animal studies and support additional partnering and IP.
Market Pulse Summary
This announcement outlines Lexaria’s 2026 R&D program, centering on one 5-week human GLP-1 study and two large animal studies with up to 18 arms, including new molecules like retatrutide and amycretin and brain-biodistribution work. It builds on earlier Phase 1b and pilot results where DehydraTECH formulations showed safety and tolerability benefits. Investors may watch enrollment timing, ethics approvals, PK outcomes, and any partnering progress that might stem from new intellectual property generated by these studies.
Key Terms
pharmacokinetic medical
pk medical
semaglutide medical
salcaprozate sodium medical
retatrutide medical
AI-generated analysis. Not financial advice.
Exciting new human and animal studies designed to enhance business opportunities
KELOWNA, BC / ACCESS Newswire / March 4, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the beginning of its 2026 research and development program (the "2026 R&D Program") designed to broaden pharmaceutical, intellectual property ("IP"), and business development opportunities through new and improved formulations.
Information on 3 new studies from the 2026 R&D Program which are representative of the Company's primary areas of focus during at least the first three quarters of the calendar year, is being released today, however these studies do not necessarily encompass the entire 2026 R&D Program.
"Our 2026 R&D Program might be the most focused on practical results that the Company has ever conducted," stated Richard Christopher, CEO of Lexaria. "These studies are specifically concentrated on increasing the likelihood of pharma industry partnerships and the creation of new intellectual property," continued Mr. Christopher. "Some of this work must intentionally remain obscure at this time since, if successful, it could likely lead to expanded new IP and patent development."
Human Study GLP-1-H26-7
With study design nearing completion, this is expected to be a 5-week parallel group study consisting of 3 different arms with primary goals of establishing safety and tolerability, as well as pharmacokinetic ("PK") evaluation, comparing salcaprozate sodium ("SNAC")-inclusive DehydraTECH-semaglutide tablet and capsule compositions to the recently launched, commercially available Wegovy® semaglutide tablets under fasted pre-dose conditions.
Generally speaking, this study will evaluate differences between DehydraTECH capsules traditionally optimized for intestinal absorption and DehydraTECH tablets experimentally optimized for primarily stomach absorption. It will also evaluate the performance of a SNAC-enabled DehydraTECH-semaglutide formulation that was not previously included in Lexaria's Phase I Human Study conducted in Australia in 2025.
Study GLP-1-H26-7 will also be designed to expand upon the findings of Human Pilot Study #1 which delivered exciting PK and safety results with an earlier iteration of SNAC-inclusive DehydraTECH-semaglutide capsules, but was limited to a single day of dosing and was, thus, incapable of achieving so-called steady-state PK results as will be targeted here. Study GLP-1-H26-7 will also be much more robust than Human Pilot Study #1, with roughly 30 subjects expected to be enrolled in each of the study arms concentrating on the tablet comparisons, and 15 subjects in the capsule study arm. While the larger study sample size increases costs, it also improves the prospective statistical reliability of the data generated, hopefully sufficient to encourage industry partnering if successful.
Lexaria is aggressively working with its third-party service providers with the intent of beginning recruitment in this study as early as April. Ethics board submissions will be made as soon as possible. The Company will provide public updates when ethics board approval has been achieved. A final study report should be expected in Q4, 2026. (All dates herein referring to calendar 2026.)
Animal Studies
Lexaria is also progressing rapidly with study design for 2 animal studies. The Company typically conducts animal study work with two main objectives: first, to establish scientific evidence supporting new concepts, procedures and formulations intended to facilitate the development of new IP through the development and filing of patent applications; and second, to test wide varieties of conditions and formulations to narrow down choices prior to potential future corroborating human study work.
Animal Study GLP-1-A26-1
Animal Study GLP-1-A26-1 is expected to be a large, single-dose study with between 8-11 different arms. Blood samples are expected to be drawn over an 8-24-hour post-dose period to quantify the PK performance of the active ingredients. We currently expect to test various SNAC-inclusive DehydraTECH-semaglutide formulations with prospective formulation performance enhancements from our earlier glucagon-like peptide-1 ("GLP-1") related work; and in separate arms, test various DehydraTECH-cannabidiol formulations where similar enhancements may be beneficial for Lexaria's cannabidiol therapeutic program pursuits.
Brain samples will also be taken since DehydraTECH has, in the past, evidenced apparent superior absorption of active ingredients into brain tissue, an area of intense interest due to the fact that GLP-1 drug performance is increasingly understood to include or even depend upon involvement of brain neurochemistry, thus making brain biodistribution vital.
A primary goal of this study will be to discover whether new and different formulation enhancements contemplated by Lexaria might enhance PK performance of either of these drug classes. Given the expected unique formulations and proprietary internal understanding of DehydraTECH capabilities, Lexaria is exploring, among other study objectives, whether it might be able to create new IP previously unknown to industry in the hopes of developing valuable proprietary technology that could be used in the oral delivery of GLP-1 and potentially other drugs.
Animal Study GLP-1-A26-1 is anticipated to begin by Q2, 2026 with a final study report expected near the end of Q3, 2026.
Animal Study GLP-1-A26-2
Animal Study GLP-1-A26-2 is expected to be a large, single-dose study with between 14-18 different arms. This study will be focused on the delivery of DehydraTECH enhanced retatrutide and amycretin, both GLP-1 drugs that Lexaria has never studied before. The inclusion of retatrutide will mark the first time that that Company has worked with a triple agonist which targets GLP-1, glucose-dependent insulinotropic polypetide ("GIP") and glucagon receptors. Also unique to Lexaria's historical research, some of the study arms will be comparing the PK performance of test articles placed endoscopically in the intestine versus being swallowed thus targeting the stomach, in order to compare and contrast formulation functionality and performance in these distinct drug delivery dosing regions gastrointenstinally.
As with Animal Study GLP-1-A26-1, a number of different formulations will also be evaluated to provide us with guidance on potential performance enhancements that may result from either the different formulation compositions or from the different routes of absorption. Blood samples are expected to be drawn over a 24-hour post-dose period to quantify the PK performance of the active ingredients.
Animal Study GLP-1-A26-2 is also anticipated to begin by Q2, 2026 with a final study report expected near the end of Q3, 2026.
Each of the above noted studies will be conducted by independent third-party service providers and individually announced with additional details once they are ready to proceed. Final designs and details are still being completed and may vary slightly from the details provided herein. Additional R&D work, not yet disclosed, may be completed during 2026.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 60 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire
FAQ
What is Lexaria (LEXX) studying in its 2026 human trial GLP-1-H26-7?
How many subjects will Lexaria (LEXX) enroll in the GLP-1-H26-7 human study?
When will Lexaria (LEXX) start its 2026 animal studies and what are their scopes?
What drugs will Lexaria (LEXX) test in Animal Study GLP-1-A26-2?
What are Lexaria's (LEXX) stated goals for the 2026 R&D Program?
What are the key risks or dependencies for Lexaria's (LEXX) 2026 studies?
